ECHO研究:肌肉骨骼超声在类风湿关节炎管理中的前瞻性观察评估
这项前瞻性两队列准实验研究比较了肌肉骨骼超声(MSUS)与常规诊疗(RC)在中重度RA需因疗效不足而调整治疗患者中的管理效果,共纳入383例(MSUS组171例,RC组212例),随访至1年。MSUS组治疗调整更多,但临床与患者报告结局无显著差异;MSUS可检出亚临床炎症并预测未来关节侵蚀。
要点
- MSUS组治疗调整次数多于RC组,调整后发生率比(95%CI)为1.4(1.1, 1.8)。
- 两组临床与患者报告结局无显著差异。
- 临床缓解的MSUS患者中50-80%滑膜炎评分≥1,37-73%侵蚀评分≥1。
核心结论
- MSUS评估有助于检出亚临床炎症并预测未来关节破坏,从而优化RA治疗与患者管理。
研究设计与样本
- 前瞻性、两队列、准实验研究,比较MSUS管理与常规诊疗,随访至1年。
- 共纳入383例中重度RA因疗效不足需调整治疗的患者,MSUS组171例,RC组212例。
主要发现
- 基线时MSUS组使用生物制剂DMARD比例高于RC组(50.3% vs 36.8%,P=0.008),RC组使用非生物制剂DMARD比例更高(91.5% vs 84.2%,P=0.027)。
- 随访期间MSUS组RA治疗调整次数多于RC组,调整后发生率比(95%CI)为1.4(1.1, 1.8),涉及糖皮质激素、非生物制剂DMARD和生物制剂DMARD。
- 两组临床与患者报告结局无显著差异。
- 整个研究中,临床缓解的MSUS患者中50-80%滑膜炎评分≥1,37-73%侵蚀评分≥1。
- 基线滑膜炎与随访期间关节侵蚀存在显著关联。
临床怎么用
- 对中重度RA需调整治疗者,可考虑用MSUS评估亚临床滑膜炎与侵蚀风险以辅助治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Since the creation of the Canadian Rheumatology Ultrasonography Society, an increasing number of rheumatologists has been trained in the use of musculoskeletal US (MSUS). We compared the effectiveness of MSUS to routine care (RC) as a disease management tool in patients with moderate-to-severe RA requiring a treatment change due to lack of efficacy. The predictive value of MSUS was also assessed. METHODS: This was a prospective, two-cohort, quasi-experimental study. Patients were managed either with MSUS (within the Canadian Rheumatology Ultrasonography Society) or as per RC for up to 1 year. Main outcomes included Clinical Disease Activity Index low disease activity/remission, DAS28 low disease activity/remission, MSUS scores, patient satisfaction and perception of participation in disease management. RESULTS: A total of 383 patients were enrolled (MSUS: n = 171; RC: n = 212). At baseline, a greater proportion of MSUS patients were treated with a biologic DMARD (50.3 vs 36.8%; P = 0.008) while more patients treated per RC received a non-biologic DMARD (84.2 vs 91.5%; P = 0.027). During follow-up, a greater number of RA treatment modifications was applied in the MSUS group compared with RC [adjusted incidence rate ratio (95% CI): 1.4 (1.1, 1.8)], including steroids, non-biologic DMARDs and biologic DMARDs. Regarding clinical and patient-reported outcomes, no remarkable differences were observed between groups. However, throughout the study, 50-80% of MSUS patients in clinical remission has a MSUS synovitis score of ≥1, and 37-73% an erosion score of ≥1. Significant associations were observed between baseline synovitis and joint erosion during follow-up. CONCLUSION: MSUS assessments can be useful in detecting subclinical levels of inflammation and predicting future joint deterioration, thus allowing optimization of RA treatment and patient care.
引用
- Stein M, Vaillancourt J, Rampakakis E, et al. Prospective observational study to evaluate the use of musculoskeletal ultrasonography in rheumatoid arthritis management: the ECHO study. Rheumatology (Oxford). 2020. PMID: 32011706. doi:10.1093/rheumatology/keaa004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。